Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market: A Key Factor Shaping the Future of the Non-Alcoholic Steatohepatitis Biomarkers Market in 2025

What industry-specific factors are fueling the growth of the non-alcoholic steatohepatitis biomarkers market?
The rise in liver cancer cases is anticipated to spur the expansion of the non-alcoholic steatohepatitis biomarkers market. This type of cancer indicates the formation of malignant tumors within the liver, either originating from the liver itself (primary liver cancer) or metastasizing to the liver from different parts of the body (secondary or metastatic liver cancer). Biomarkers for Non-alcoholic steatohepatitis (NASH) are employed in diagnosing liver cancer early, tracking disease progression, and evaluating treatment responses. They also offer prognostic data and can minimize the necessity for invasive procedures. For example, the World Cancer Research Fund, a non-profit organization based in the UK, reported approximately 866,136 new liver cancer cases worldwide in 2022, making it the 6th most prevalent cancer globally. Consequently, this increase in liver cancer prevalence is propelling the expansion of the non-alcoholic steatohepatitis biomarkers market.

Get Your Non-Alcoholic Steatohepatitis Biomarkers Market Report Here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

What Is the projected market size and growth rate for the non-alcoholic steatohepatitis biomarkers market?
The market size for biomarkers of non-alcoholic steatohepatitis has seen an extraordinary surge in recent years. The projected growth is from $1.36 billion in 2024 to $1.7 billion in 2025, displaying a compound annual growth rate (CAGR) of 24.8%. Factors that contribute to this growth in the previous period include diabetes and metabolic syndrome, increased awareness and screening initiatives, limitations of liver biopsy, regulatory endorsements, a shift towards individualised medicine, and clinical trials for NASH.

The market for non-alcoholic steatohepatitis biomarkers is predicted to experience significant growth in the coming years. It is projected to expand to $3.86 billion by 2029, with an impressive compound annual growth rate (CAGR) of 22.8%. Various factors are driving this predicted growth during the forecast period, including the development of new therapies, the advancement of precision medicine, patient advocacy efforts, the incorporation of multi-omics data, and improved patient engagement. Key trends during this period are anticipated to be telemedicine and remote patient monitoring, groundbreaking diagnostic platforms, international research collaborations, advancements in technology for biomarker discovery, the integration of artificial intelligence (AI), and the inclusion of imaging biomarkers.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

What new trends are reshaping the non-alcoholic steatohepatitis biomarkers market and its opportunities?
Innovations in technology are becoming a significant trend in boosting the non-alcoholic steatohepatitis biomarkers market's popularity. To consolidate their market position, leading companies focus on creating unique solutions. For instance, in October 2022, an exclusive five-year licensing agreement was struck between GENFIT, a biopharmaceutical company based in France, and LabCorp, a life sciences firm from the US, for GENFIT's NIS4 technology. This technology is a transformative, multi-biomarker algorithm designed specifically to detect non-alcoholic steatohepatitis (NASH) in patients, and those with significant to advanced fibrosis (F > 2), also known as at-risk NASH. LabCorp, as part of this deal, will develop a blood-based molecular diagnostic test using NIS4 technology in the US and Canada to provide healthcare professionals with widespread access.

What major market segments define the scope and growth of the non-alcoholic steatohepatitis biomarkers market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented -

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9002

Which region dominates the non-alcoholic steatohepatitis biomarkers market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the non-alcoholic steatohepatitis biomarkers industry growth?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

What Is Covered In The Non-Alcoholic Steatohepatitis Biomarkers Global Market Report?

• Market Size Forecast: Examine the non-alcoholic steatohepatitis biomarkers market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the non-alcoholic steatohepatitis biomarkers market for a structured understanding.
• Key Players Overview: Analyze major players in the non-alcoholic steatohepatitis biomarkers market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the non-alcoholic steatohepatitis biomarkers market.
• Segment Contributions: Evaluate how different segments drive overall growth in the non-alcoholic steatohepatitis biomarkers market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the non-alcoholic steatohepatitis biomarkers market.
• Industry Challenges: Identify potential risks and obstacles affecting the non-alcoholic steatohepatitis biomarkers market.
• Competitive Landscape: Review strategic developments in the non-alcoholic steatohepatitis biomarkers market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.